Unusual-IV
Financiado
Intraveneously injected unusual nanoparticles in the clinic
"Cancer. Cardiovascular disease. Autoimmune disease. Neurological disease. Rheumatoid arthritis.
What do these diseases have in common? -Chronic inflammation.
In recognition of this, the NIH organised a focus session on the cur...
"Cancer. Cardiovascular disease. Autoimmune disease. Neurological disease. Rheumatoid arthritis.
What do these diseases have in common? -Chronic inflammation.
In recognition of this, the NIH organised a focus session on the current clinical needs around inflammation in 2019, stating Tools to locate and monitor inflammation are critical for developing effective interventions to arrest inflammation and promote its resolution. Clinical speakers described their needs for image‐based capabilities ... to guide treatment planning and undertake necessary interventions…All speakers agreed that multiple inflammatory measures should be acquired longitudinally to comprehend the dynamics of unresolved inflammation that leads to disease development.
As an example, atherosclerosis- the #1 killer in developed countries- is now known to be a chronic inflammatory disease . Mounting clinical evidence suggests that effective treatment requires a reduction in both LDL levels (cholesterol) and underlying inflammation. However, a simple reduction in inflammation, measured by serum markers, has not proven successful in the clinic . Thus, as also found by the NIH workshop, treatment plans must take into account the inflammation status in the vessel walls in a longitudinal manner, which cannot be measured by blood tests.
This is no small task, as chronic inflammation is often asymptomatic until disease has developed. Pubmed has over 36,000 review articles on chronic inflammation. The ultimate goal is to have clinical noninvasive biomarkers of inflammation that can help in diagnosis, predict outcome and assess response to therapy or preventative strategy.
Overall, there is an unmet need to noninvasively diagnose inflammation, that can be used in conjunction with conventional biofluid and biopsy markers. This is particularly the case when treatment includes longterm preventative lifestyle changes. Noninvasive clinical imaging could be the solution."
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2021-07-29
Fecha Fin: 2023-01-31
Fecha Fin: 2023-01-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-01-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2020-POC:
Call for proposals for ERC Proof of Concept Grant
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
CENYA IMAGING B.V.
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
337.80K€ |
Participante